Koos de Wit

Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial

Elisa Pose, Laura Napoleone, Ahmed Adel Amin et al. · ˜The œLancet. Gastroenterology & hepatology · 2019 · 135 citations · Full text

Drug Safety, Hepatology, Decompensated Cirrhosis +8

Prevalence, distribution and risk of sessile serrated adenomas/polyps at a center with a high adenoma detection rate and experienced pathologists

Joep IJspeert, Koos de Wit, Manon van der Vlugt et al. · Endoscopy · 2016 · 90 citations

Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial)

Koos de Wit, Jelte J. Schaapman, Frederik Nevens et al. · BMJ Open Gastroenterology · 2020 · 40 citations · Full text

Variable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study

Rosalie C. Oey, Koos de Wit, Adriaan Moelker et al. · Alimentary Pharmacology & Therapeutics · 2018 · 39 citations · Full text

Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

Elsa Solà, Elisa Pose, Daniela Campion et al. · Journal of Hepatology · 2020 · 35 citations · Full text